Molecular Subtypes of Diffuse Large B-Cell Lymphoma Based on Immunophenotyping and Its Prognosis

Abstract

Diffuse large-B cell lymphoma (DLBCL) is a malignancy due to abnormalities of mature B cells at various stages of differentiation. Diffuse large-B cell lymphoma is multifactorially complex and is the subtype of non-Hodgkin's lymphoma (LNH) with the most diagnosed cases in the world. Diffuse large B-cell lymphoma is classified into two molecular subtypes based on cell of origin (COO) and immunophenotyping: germinal center B-cell-like (GCB) and activated B-cell-like (ABC or non-GCB). This classification is important in determining the initial management and prognosis of patients. In this literature review, a comprehensive article exploration strategy was applied in various online research journal databases. The databases used in the search are: Pubmed, ScienceDirect, and Google Scholar. In the search, the keywords used were: diffuse large B-cell lymphoma; DLBCL; cell of origin; COO; immunophenotyping; and prognosis. The research articles presented in this literature review must meet the inclusion criteria: (1) the year of publication of the article is not more than 10 years; (2) the discussion of the article is related to the molecular subtype of DLBCL and its prognosis; (3) the article must be accessible in full-text; and exclusion criteria: (1) the language used in writing articles other than English and Indonesian, so that 10 articles could be analyzed based on topic suitability. The role of DLBCL molecular subtypes based on immunophenotyping in determining the prognosis or outcome of patients is still debatable today. There is a need to evaluate the use of predictive and prognostic markers of DLBCL, as well as the involvement of a larger number of patients in prospective clinical trials so that differences in outcomes (EFS, PFS, OS, DFS, dan RFS) between the GCB-DLBCL and non-GCB-DLBCL (ABC-DLBCL) groups can be obtained.